<DOC>
	<DOCNO>NCT00376337</DOCNO>
	<brief_summary>To evaluate efficacy safety micafungin patient proven invasive aspergillosis refractory intolerant previous systemic antifungal therapy . To compare efficacy safety micafungin therapy active control arm</brief_summary>
	<brief_title>Micafungin Salvage Mono-therapy Invasive Aspergillosis</brief_title>
	<detailed_description>This phase II , multicentre , prospective , active-controlled , open-label , 2:1 randomise parallel group clinical study . Patients stratify accord baseline infection status baseline neutropenic status : - Intolerant previous antifungal therapy - Refractory previous antifungal therapy ; progression infection - Refractory previous antifungal therapy ; failure improve In case , criterion intolerant refractory fulfilled time patient consider refractory . - Neutropenic ( absolute neutrophil count ( ANC &lt; 500 cells/mm3 ) - Non neutropenic ( ANC &gt; = 500 cells/mm3 )</detailed_description>
	<mesh_term>Aspergillosis</mesh_term>
	<mesh_term>Micafungin</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<criteria>Adult patient HSCT , acute leukaemia myelodysplastic syndrome , proven ( probable case pulmonary aspergillosis ) invasive aspergillosis refractory intolerant amphotericin B voriconazole product Patients allergic bronchopulmonary aspergillosis , chronic pulmonary aspergillosis , aspergilloma , sinus aspergillosis external otitis ; patient previous salvage therapy current episode fungal infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Invasive Aspergillosis</keyword>
	<keyword>Salvage Therapy</keyword>
	<keyword>Micafungin</keyword>
</DOC>